Eric Campeau

Company: Thryv Therapeutics

Job title: Vice President Translational Research

Seminars:

Developing Novel Small Molecule Inhibitors of Serum & Glucocorticoid Regulated Kinase 1 (SGK1) for the Treatment of Fibrotic Diseases 3:00 pm

SGK1 is involved in the integration of pro-fibrotic signalling through the TGFb, PI3K, and MAPK pathways Inhibiting SGK1 decreases expression of several fibrotic markers in vitro and in vivo Leveraging how SGK1 inhibition offers a novel approach to address several pro-fibrotic pathways simultaneouslyRead more

day: Day Two